Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 976 of 6351
-
Can Trauma-Focused coping skills boost HIV suppression in women?
Disease control CompletedImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. We propose a full-scale randomized controlled trial to examine the effect of ImpACT+…
Sponsor: Columbia University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Smart sensors at home could spot frailty early and lend a helping hand
Knowledge-focused CompletedThe investigators seek to construct a novel, multimodal, distributed system that facilitates a new paradigm of home-based medical surveillance and treatment for frail older adults centered on timely diagnosis of movement system impairments and personalized intervention. Measureme…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can genetics predict who responds to heart failure treatment?
Knowledge-focused Recruiting nowA biobank within the Swedish national heart failure quality registry SwedeHF.
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Immunotherapy boosts chemo to wipe out hidden leukemia cells
Disease control OngoingThis phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Chemotherapy drugs, such as cytarabine, idarubicin, and daunorubicin, work in different ways to stop…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis phase II trial studies how well azacitidine and venetoclax with or without pembrolizumab work in treating older patients with newly diagnosed acute myeloid leukemia. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of tumor cells, either by …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Milder treatment after robotic surgery may cut side effects for HPV throat cancer patients
Disease control OngoingThis study will enroll patients with HPV-associated oropharyngeal cancer, undergoing resection of all gross visible disease at the primary site and in the lymph nodes. A total of 40 patients who have had or will require surgery to remove cancer cells prior to starting chemoradiat…
Phase 2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New shot could slash Sky-High cholesterol in teens with rare gene condition
Disease control CompletedThis was a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in adolescents with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kids with brain tumors: drug combo trial launches
Disease control OngoingThis phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has c…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New daily shot could replace calcium pills for rare hormone disorder
Disease control CompletedDuring the first 26 weeks of the trial, participants were randomly assigned to one of two groups: one group received TransCon PTH and one group received placebo. All participants started with study drug at a dose of 18 mcg/day and were individually and progressively titrated to a…
Phase 3 • Sponsor: Ascendis Pharma Bone Diseases A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New malaria combo shows promise in kids – could fight drug resistance
Disease control CompletedThis study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to \< 18 years of age) with uncomplicated P. falciparum malaria. The…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Wearable tech could spot Post-Surgery problems early
Symptom relief OngoingThis phase III trial compares a home-based telemonitoring program that collects symptom and daily step information to surgeon only care in improving recovery and stopping complications within 30 days after surgery in patients with gastrointestinal, genitourinary, or gynecologic c…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Could a daily aspirin save mothers and babies from hypertension risks?
Prevention Recruiting nowA randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg/day started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.
Phase 3 • Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control OngoingPatients who have histologically confirmed metastatic or unresectable (not amenable to curative therapy) breast cancer may be screened for eligibility. All patients must have HER2 negative breast cancer with the identified PIK3CA mutation and received at least one line of endocri…
Phase 2 • Sponsor: Marina N Sharifi • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody shows promise in cutting COPD attacks for smokers
Disease control CompletedPrimary Objective: Primary population (former smokers cohort): * Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary popula…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a common diuretic protect the liver and heart in children born with one heart chamber?
Disease control CompletedThe purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationsh…
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for tough stomach cancer
Disease control OngoingThe purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer. Nivolumab is an antibody, like the proteins made by the immune system to prote…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Less fat, better brains: study tests lipid reduction to protect preemies
Disease control OngoingThe purpose of this study is to evaluate the effect of usual versus reduced lipid intake on unbound bilirubin levels, brainstem auditory evoked responses, and neurodevelopmental outcome at 2 years in extremely preterm infants.
Phase 2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo before liver surgery shows promise in early trial
Disease control OngoingThis phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Dogs on the scent: can they sniff out cancer?
Diagnosis CompletedThe goal of this study is to show that trained detection dogs can identify breast, lung, prostate or colorectal cancer by sniffing masks containing breath samples. In this study, individuals who will undergo cancer screening at an integrated cancer prevention center or biopsy for…
Sponsor: SpotitEarly • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
One-Week radiation may cut lymphedema risk in breast cancer patients
Disease control OngoingThe primary objective of this study is to determine if hypofractionated RT delivered over 1 week to the breast or chest wall and regional nodes (26Gy in 5 daily fractions) following BCS or mastectomy, is non-inferior to conventional fractionation to the breast or chest wall and r…
Phase 3 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC